Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quarfloxin
- Development stage
- Phase 2
- Lead developer
- Senhwa Biosciences
- Modality
- Small Molecules
- Administration
- Intravenous[3][4]
01
Overview
Quarfloxin is a small molecule antineoplastic agent and a fluoroquinolone derivative developed as an investigational cancer therapeutic. Its mechanism of action involves selectively disrupting the interaction between nucleolin protein and G-quadruplex DNA structures in ribosomal DNA (rDNA) within the nucleolus, thereby inhibiting RNA polymerase I-mediated transcription. This disruption impairs ribosomal RNA (rRNA) biogenesis, leading to apoptosis in cancer cells—a process that is particularly amplified in malignancies due to their increased rRNA synthesis demands. Quarfloxin was primarily investigated for use in neuroendocrine tumors, carcinoid tumors, lymphoma, and advanced solid tumors. Clinical development was discontinued after phase II trials due to lack of significant clinical benefit or strategic reasons[1][3][4][5][6].
- Brand names
- Quarfloxin
- Other names
- ItarnafloxinItarnafloxinaItarnafloxineItarnafloxinumQuarfloxacin
02
Targets
NCL (Nucleolin)PfG4 (Plasmodium falciparum G-quadruplex DNA)Pol I (RNA polymerase I)rDNA G4 (Ribosomal DNA G-quadruplex)telomeric G4 (Telomeric DNA G-quadruplex)
Beyond the preview
Go deeper on quarfloxin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quarfloxin.